These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 20028919)

  • 1. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon.
    Ng CS; Wang X; Faria SC; Lin E; Charnsangavej C; Tannir NM
    AJR Am J Roentgenol; 2010 Jan; 194(1):166-71. PubMed ID: 20028919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular Tumor Burden as a New Quantitative CT Biomarker for Predicting Metastatic RCC Response to Antiangiogenic Therapy.
    Smith AD; Zhang X; Bryan J; Souza F; Roda M; Sirous R; Zhang H; Vasanji A; Griswold M
    Radiology; 2016 Nov; 281(2):484-498. PubMed ID: 27603788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
    Fournier LS; Oudard S; Thiam R; Trinquart L; Banu E; Medioni J; Balvay D; Chatellier G; Frija G; Cuenod CA
    Radiology; 2010 Aug; 256(2):511-8. PubMed ID: 20551183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined immunotherapy with low-dose IL-2 plus IFN-alpha for metastatic renal cell carcinoma: survival benefit for selected patients with lung metastasis and serum sodium level.
    Akaza H; Tsukamoto T; Fujioka T; Tomita Y; Kitamura T; Ozono S; Miki T; Naito S; Zembutsu H; Nakamura Y
    Jpn J Clin Oncol; 2011 Aug; 41(8):1023-30. PubMed ID: 21642665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2017 Feb; 52(2):103-110. PubMed ID: 27513367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
    Smith AD; Lieber ML; Shah SN
    AJR Am J Roentgenol; 2010 Jan; 194(1):157-65. PubMed ID: 20028918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma.
    Faria SC; Ng CS; Hess KR; Phongkitkarun S; Szejnfeld J; Daliani D; Charnsangavej C
    AJR Am J Roentgenol; 2007 Aug; 189(2):378-85. PubMed ID: 17646464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic contrast-enhanced computed tomography as a potential biomarker in patients with metastatic renal cell carcinoma: preliminary results from the Danish Renal Cancer Group Study-1.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2014 Sep; 49(9):601-7. PubMed ID: 24691140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    AJR Am J Roentgenol; 2010 Jun; 194(6):1470-8. PubMed ID: 20489085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study.
    Felsch M; Zaim S; Dicken V; Lehmacher W; Scheuring UJ
    Acta Radiol; 2017 Feb; 58(2):249-255. PubMed ID: 27083205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline perfusion CT parameters as potential biomarkers in predicting long-term prognosis of localized clear cell renal cell carcinoma.
    Wang Y; Cui L; Zhang J; Zhang L; Zhang J; Zhao X; Chen Y
    Abdom Radiol (NY); 2019 Oct; 44(10):3370-3376. PubMed ID: 31399787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis of renal cell carcinoma: perfusion CT findings.
    Chen Y; Zhang J; Dai J; Feng X; Lu H; Zhou C
    Abdom Imaging; 2010 Oct; 35(5):622-8. PubMed ID: 19763683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative Response Criteria and Clinical Risk Factors for Assessing Tumor Response in Patients With Metastatic Renal Cell Carcinoma Who Are Receiving Salvage Therapy.
    Kang HC; Gupta S; Wei W; Lu L; Matrana MR; Tannir NM; Choi H
    AJR Am J Roentgenol; 2017 Dec; 209(6):1278-1284. PubMed ID: 29064751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
    Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
    Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.
    Han KS; Jung DC; Choi HJ; Jeong MS; Cho KS; Joung JY; Seo HK; Lee KH; Chung J
    Cancer; 2010 May; 116(10):2332-42. PubMed ID: 20225226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
    Garcia JA; Mekhail T; Elson P; Wood L; Bukowski RM; Dreicer R; Rini BI
    BJU Int; 2012 Jan; 109(1):63-9. PubMed ID: 21244601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.
    Kim SH; Park WS; Kim SH; Seo HK; Joung JY; Lee KH; Chung J
    PLoS One; 2017; 12(5):e0177975. PubMed ID: 28562690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
    Kankuri M; Pelliniemi TT; Pyrhönen S; Nikkanen V; Helenius H; Salminen E
    Cancer; 2001 Aug; 92(4):761-7. PubMed ID: 11550145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.